LEHI, Utah., Sept. 12, 2024 /PRNewswire/ — Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the remarkable preclinical results of its oral small molecule GLP-1 agonist, BLX-7006. In a recent study, BLX-7006 demonstrated…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
LEHI, Utah and LOUISVILLE, Ky., Oct. 14, 2024 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that it will report financial results for the third quarter ended […]
SPRINGVILLE, Utah, Jan. 27, 2026 /PRNewswire/ — Sisel International has announced the launch of SiselRIPT™ Sunburst, a new tropical-inspired flavor that expands the company’s performance nutrition portfolio and reinforces its commitment to clean, science-informed supplementation […]
Q3 revenue growth of 12% year-over-year Q3 net income of $30.6 million and non-GAAP net income of $67.8 million Q3 net income margin of 11%; adjusted EBITDA margin of 42% Raising revenue and adjusted EBITDA […]
Copyright © 2026 Biotech Networks
